AB-729-001

A Phase 1a/1b clinical trial evaluating the safety, tolerability, and PK/PD of single and multiple-ascending dose of AB-729 in healthy subjects and patients with cHBV infection.

Preliminary data suggest that AB-729 is generally safe and well tolerated through 48 weeks of dosing and long-term suppression of HBsAg with AB-729 results in increased HBV-specific immune response. Patients are continuing to be followed post-treatment.

ANZCTR.org